Navigation Links
Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
Date:8/3/2015

NESS ZIONA, Israel, August 3, 2015 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced it received the statistical analysis of results from a study which demonstrates that BiondVax's universal flu vaccine (M-001), administered in the BVX-005 phase II trial which took place in 2012, provided participants with increased immunogenicity against future strains which did not exist at the time of the study- in particular the current newly emerged H3N2 influenza (flu) strain that caused the epidemic in the United States in 2015.

In 2012, 120 elderly participants aged 65 or over, participated in the BVX-005 trial. This trial was concluded successfully, demonstrating induction of both humoral and cellular immune responses to BiondVax's vaccine and to multiple influenza viruses. In that trial, 90 participants were injected with the M-001 universal flu vaccine a few weeks prior to immunization with TIV (the commercially available seasonal flu vaccine of that time). The remaining group of 30 was a control group which was provided with a placebo followed by the TIV.

Three years later, in 2015, BiondVax exposed the blood plasma samples from the BVX-005 participants (taken following the completion of the trial in 2012) to the current influenza flu epidemic H3N2 strain (A/Switzerland/9715293/2013), which in 2012 did not yet exist.

BiondVax examined the immunogenicity (HAI) antibodies in each blood plasma sample and found significantly increased level of protective antibodies against the H3N2 strain in the samples taken from participants that received the M-001 vaccine in comparison to the control group. An average of 50% or greater of the participants in the experimental group receiving M-001 showed immunogenicity against this new strain versus only 10% on average in the control group, a result which has statistically high significance.  

This concurs with the similar results found in BiondVax's recent BVX-006 phase II trial, showing increased antibody response to the H3N2 epidemic flu strain in those that received BiondVax's universal vaccine, although it was not included in the commercially available seasonal flu vaccine of the 2014/15 season. Management believe that this data confirms the universal nature of BiondVax's vaccine, protecting against all types of flu strains.

Ron Babecoff, BiondVax's President and CEO, commented, "We are happy that the participants which received our vaccine in the trial three years ago present a higher immunogenicity, even to actual flu strains in circulation now. The independently provided statistical analysis we reported today is very important as it demonstrates that M-001 provides a safety net by broadening the immunogenicity to existing and future flu strains - in this case, against a specific flu strain that back when the trial was conducted, did not yet exist. If our vaccine was approved by the necessary regulatory bodies and available in the market during the last winter, we believe that the recent epidemic could have been prevented. These results are another important data point showing the importance of our work for global public health and in particular for the elderly which are most vulnerable to this dangerous virus."

About BiondVax Pharmaceuticals Ltd 

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Forward Looking Statements  

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, uncertainty of clinical trial results or regulatory approvals or clearances, final results from subsequent clinical trials, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

For further information, please contact:
Company Contact
Dr Limor Chen, Director of  BD
limor.c@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
investor.relations@biondvax.com


'/>"/>
SOURCE Biondvax Pharmaceuticals Ltd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
2. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
3. Independent Pharmacy Cooperative to Distribute Promescent, Topical Medication for Premature Ejaculation
4. American Pacific Board Continues Focus On Corporate Governance With Appointment Of Independent Lead Director
5. Leica Biosystems Launches Independently* Qualified Menu of IHC Antibodies for Hematopathology
6. Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
7. Hologic Expands its Board of Directors with Appointment of Two Independent Directors and Engages Chairman of Mt. Sinai Radiology Department as Scientific Advisor
8. Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis
9. Biocom CEO Joe Panetta Appointed to California Institute for Regenerative Medicines Independent Citizens Oversight Committee by Governor Jerry Brown
10. WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director
11. Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... The Telehealth Secrets ... of Viome Naveen Jain, MDLIVE founder Randy Parker, NBC Comcast, senior vice president ... , The 4th Annual Telehealth Secrets conference brings together nationally recognized health innovators, ...
(Date:9/11/2019)... Calif. (PRWEB) , ... September 11, 2019 , ... “We ... wait,” exclaimed English teacher Mary Gregoski, after learning she had won a $7,500 School ... her 10th year teaching at Palmer Public School in Palmer, Nebraska. , Mary ...
(Date:9/9/2019)... (PRWEB) , ... September 09, 2019 , ... ... the minimally invasive benefits that laser dentistry provides. The dentists in Clearwater, FL, ... treatments, including cavities and dental fillings as well as gum disease ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s ... Hesano is an understanding, caring and highly skilled Obstetrician/Gynecologist. She approaches patients ... Hesano strives to ensure that each visit is comfortable, patient-focused, and that every ...
(Date:9/11/2019)... ... ... Dimensional Insight®, a data management, analytics and performance management company, ... Boston. To be held on Saturday, Sept. 28 on the Boston Common, the event ... St. Jude Children’s Research Hospital®. , “At Dimensional Insight, we believe that ...
(Date:9/9/2019)... , ... September 09, 2019 , ... Cardinal Park Family ... two decades and counting. The practice offers family dentistry , laser gum disease ... This year marks the 20th year that Cardinal Park Family Dental Care has provided ...
(Date:9/8/2019)... ... September 09, 2019 , ... Stetson University ... Best Regional Universities – South, released today. In addition, Stetson appears on five additional ... 11; Most Innovative Universities, No. 14; Campus Ethnic Diversity, No. 34; and a new ...
(Date:9/8/2019)... ... 2019 , ... The Plantrician Project is pleased to introduce WeTheTrillions ... where close to 1000 medical professionals from 25 countries, will gather in Oakland ... of whole food, plant-based nutrition in clinical practice. , “WeTheTrillions is ...
Breaking Medicine News(10 mins):